Attached files

file filename
EX-99.1 - EX-99.1 - ASSEMBLY BIOSCIENCES, INC.v240371_ex99-1.htm
EX-99.2 - EX-99.2 - ASSEMBLY BIOSCIENCES, INC.v240371_ex99-2.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 14, 2011

 
VENTRUS BIOSCIENCES, INC.
 
 
(Exact name of registrant as specified in its charter)
 


Delaware
001-35005
20-8729264
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer ID Number)
   
99 Hudson Street, 5th Floor, New York, New York
10013
(Address of principal executive offices)
(Zip Code)


Registrant’s telephone number, including area code
(646) 706-5208


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 8.01.  Other Events.
 
On November 14, 2011, Ventrus Biosciences, Inc. issued a press release to report top line results of a research study commissioned by Ventrus on the U.S. market for hemorrhoids and iferanserin (VEN-309), as well as give an update on the progress of its ongoing Phase III pivotal trial for VEN-109 for the treatment of asymptomatic hemorrhoids.  A copy of the related press release and PowerPoint presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2 respectively and are incorporated herein by reference. 
 
Item 9.01. Financial Statements and Exhibits.
 
 
(d)
Exhibits
   
Exhibit No.
Description
   
99.1
Press release dated November 14, 2011.
99.2
Slide presentation of November 14, 2011.
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
VENTRUS BIOSCIENCES, INC.
 
     
       
Date:  November 14, 2011             
By:
/s/ David J. Barrett  
    David J. Barrett, Chief Financial Officer